Literature DB >> 32258523

Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis.

Praveen Sharma1, Anil Arora1.   

Abstract

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are commonest causes of chronic liver disease in developing as well as developed countries. Their incidence has increased due to widespread easy availability of alcohol and sedentary life style of people. NAFLD is a spectrum which includes fatty liver (NAFL) which is considered benign disease, steatohepatitis (NASH) which indicates ongoing injury to liver and cirrhosis of liver. Similarly, ALD spectrum comprises simple steatosis, alcoholic hepatitis, and cirrhosis and its complications. Most of the time there is significant overlap between these diseases and clinical presentation depends upon the stage of liver disease. Most of the NAFLD patients are asymptomatic and diagnosed to have fatty liver while undergoing routine health check up. ALD requires significant history of alcohol intake which is supportive by radiological and biochemical tests. In both NAFLD and ALD patients, liver enzymes are seldom raised beyond five times the upper limit of normal. Liver biopsy is required for diagnosis of NASH as it is a histological diagnosis and sometimes in alcoholic hepatitis for confirmation if diagnosis is in doubt. Non-invasive markers and prognostic scores have been developed for avoiding liver biopsy in assessment and treatment response of NASH and alcoholic hepatitis patients. 2020 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Alcoholic liver disease (ALD); clinical presentation; diagnosis; non-alcoholic fatty liver disease (NAFLD); spectrum

Year:  2020        PMID: 32258523      PMCID: PMC7063523          DOI: 10.21037/tgh.2019.10.02

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  16 in total

1.  Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liver-Enriched Transcription Factors and Functional Proteins in End-Stage Cirrhotic Human Hepatocytes.

Authors:  Edgar N Tafaleng; Amitava Mukherjee; Alejandro Soto-Gutierrez; Ira J Fox; Aaron Bell; Kazutoyo Morita; Jorge Guzman-Lepe; Nils Haep; Rodrigo M Florentino; Ricardo Diaz-Aragon; Carla Frau; Alina Ostrowska; Joshua R Schultz; Paolo G V Martini
Journal:  Hepatol Commun       Date:  2021-07-01

Review 2.  Emerging Roles of SIRT1 in Alcoholic Liver Disease.

Authors:  Ruixue Ren; Ziming Wang; Miaomiao Wu; Hua Wang
Journal:  Int J Biol Sci       Date:  2020-10-17       Impact factor: 6.580

Review 3.  Changes in Glutathione Content in Liver Diseases: An Update.

Authors:  Mariapia Vairetti; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Andrea Ferrigno; Clarissa Berardo
Journal:  Antioxidants (Basel)       Date:  2021-02-28

Review 4.  A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Marinela Krizanac; Paola Berenice Mass Sanchez; Ralf Weiskirchen; Anastasia Asimakopoulos
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

5.  Osteocalcin prevents insulin resistance, hepatic inflammation, and activates autophagy associated with high-fat diet-induced fatty liver hemorrhagic syndrome in aged laying hens.

Authors:  X L Wu; X Y Zou; M Zhang; H Q Hu; X L Wei; M L Jin; H W Cheng; S Jiang
Journal:  Poult Sci       Date:  2020-10-12       Impact factor: 3.352

Review 6.  Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation.

Authors:  Li Qi; Wanlin Dai; Jing Kong; Yu Tian; Yongsheng Chen
Journal:  J Physiol Biochem       Date:  2021-07-24       Impact factor: 4.158

7.  Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score.

Authors:  Yoichi Iwasaki; Kazuki Shiina; Chisa Matsumoto; Hiroki Nakano; Masatsune Fujii; Akira Yamashina; Taishiro Chikamori; Hirofumi Tomiyama
Journal:  J Atheroscler Thromb       Date:  2020-07-23       Impact factor: 4.928

Review 8.  Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.

Authors:  Eline Geervliet; Ruchi Bansal
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

9.  Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity.

Authors:  Jesús Funuyet-Salas; María Ángeles Pérez-San-Gregorio; Agustín Martín-Rodríguez; Manuel Romero-Gómez
Journal:  Int J Environ Res Public Health       Date:  2021-03-28       Impact factor: 3.390

10.  Proposal of a Preoperative CT-Based Score to Predict the Risk of Clinically Relevant Pancreatic Fistula after Cephalic Pancreatoduodenectomy.

Authors:  Marius Lucian Savin; Florin Mihai; Liliana Gheorghe; Corina Lupascu Ursulescu; Dragos Negru; Ana Maria Trofin; Mihai Zabara; Vlad Nutu; Ramona Cadar; Mihaela Blaj; Oana Lovin; Felicia Crumpei; Cristian Lupascu
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.